Immunosuppression in Inflammatory Cardiomyopathy and Parvovirus B19 Persistence
Key result
Immunosuppression achieves similar resolution of inflammatory infiltrates in B19V-positive and virus-negative patients.
- n=68
Why the study?
Whether immunosuppressive treatment benefits patients with inflammatory cardiomyopathy and parvovirus B19 persistence, which does not represent active infection, is uncertain.
Does a 6-month course of prednisolone and azathioprine improve LVEF and reduce inflammation similarly in B19V-positive and virus-negative patients with inflammatory cardiomyopathy?
Comparison
B19V-positive versus virus-negative patients receiving prednisolone and azathioprine plus standard heart failure medication
Design
Single-centre observational investigation
Follow-up
6 months with extended observation at mean 13 months
Authors
Discussion
Loading...
Member takes
Implication
May refine risk stratification among B19V-positive HF patients; leaves open whether targeting inflammation or viral activity improves outcomes.
Study Design
Type
Observational (n=68)
Multicenter
No
Structured PICO
Does a 6-month course of prednisolone and azathioprine improve LVEF and reduce inflammation similarly in B19V-positive and virus-negative patients with inflammatory cardiomyopathy?
P
Population
68 patients with endomyocardial biopsy-proven inflammatory cardiomyopathy (51 B19V-positive and 17 virus-negative) treated with a 6-month course of prednisolone and azathioprine.
E
Exposure
6-month course of prednisolone and azathioprine in addition to standard heart failure medication.
C
Comparator
Virus-negative patients with inflammatory cardiomyopathy receiving the same 6-month course of prednisolone and azathioprine (comparison of treatment response based on viral status).
O
Outcome
Changes in systolic left ventricular ejection fraction (LVEF, %), B19V viral genome copy numbers, and grade of inflammation at 6 months.surrogate
Main Result
Absolute Event Rate: 66% vs 70.5%
Immunosuppressive treatment with prednisolone and azathioprine safely improves LVEF and resolves inflammation in inflammatory cardiomyopathy patients with B19V persistence, yielding similar benefits to virus-negative patients.
Limitations
- Results need further verification in a randomized controlled trial.
- Single-centre observational investigation
- Needs further verification in a randomized controlled trial
Cite This Study
Tschöpe et al. (2019) conducted an observational in Inflammatory cardiomyopathy (n=68). Parvovirus B19 (B19V) positive status vs. Virus-negative status was evaluated on Resolution of inflammatory infiltrates. Immunosuppressive treatment with prednisolone and azathioprine led to similar resolution of inflammatory infiltrates in B19V-positive (66%) and virus-negative (70.5%) patients.